HQE1 Stock Overview
Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$1.83 |
| 52 Week Low | US$0.62 |
| Beta | 0.56 |
| 11 Month Change | -8.72% |
| 3 Month Change | -5.09% |
| 1 Year Change | -21.57% |
| 33 Year Change | -79.84% |
| 5 Year Change | -74.79% |
| Change since IPO | -77.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQE1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.2% | 2.4% | 0.8% |
| 1Y | -21.6% | -5.0% | 9.1% |
Return vs Industry: HQE1 underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: HQE1 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| HQE1 volatility | |
|---|---|
| HQE1 Average Weekly Movement | 13.8% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HQE1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HQE1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 186 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
Cytosorbents Corporation Fundamentals Summary
| HQE1 fundamental statistics | |
|---|---|
| Market cap | €48.54m |
| Earnings (TTM) | -€17.82m |
| Revenue (TTM) | €36.02m |
1.3x
P/S Ratio-2.6x
P/E RatioIs HQE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQE1 income statement (TTM) | |
|---|---|
| Revenue | US$37.74m |
| Cost of Revenue | US$14.07m |
| Gross Profit | US$23.67m |
| Other Expenses | US$42.34m |
| Earnings | -US$18.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 62.71% |
| Net Profit Margin | -49.47% |
| Debt/Equity Ratio | 106.2% |
How did HQE1 perform over the long term?
See historical performance and comparison